E. Piazza
59 works · 1,491 citations · h-index 14
Top works
- Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial
- Pharmacokinetics of VP16-213 given by different administration methods
- A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
- Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer
- Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses
- Transient blindness and seizure associated with cisplantin therapy
- Early phase pharmacokinetics of doxorubicin (adriamycin) in plasma of cancer patients during single- or multiple-drug therapy.
- High- versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: A ‘GISCAD’ phase III study
- A serological study of the cell fractions during the embryonic development of liver in chick
- Cross-over study of pharmacokinetics and haematological toxicity of 4'-epi-doxorubicin and doxorubicin in cancer patients.
- Ceravolo
- Differential pulse polarographic determination of BCNU pharmacokinetics in patients with lung cancer.
- Supportive care in patients with advanced non-small-cell lung cancer
- Single-day regimen of palonosetron (PALO) and dexamethasone (DEX) for the prevention of emesis associated with moderately emetogenic chemotherapy (MEC): Subgroup analysis from a randomized phase III trial
- Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: A randomized study
- VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma
- Adriamycin distribution in plasma and blood cells of cancer patients with altered hematocrit
- Pharmacokinetic study of intravenous and oral idarubicin in cancer patients.
- Double modulation of 5-fluorouracil in advanced colorectal cancer with low-dose interferon-α2b and folinic acid. The “GISCAD” experience
- Randomised trial of gemcitabine versus flec regimen given intra-arterially for patients with unresectable pancreatic cancer.